Update Phase 1: Mevrometostat Shows Promise in Prostate Cancer by Targeting EZH2
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxThe Microbiome: A Frontline Barrier and Emerging Ally in Cancer Treatment
/0 Comments/in Clinical Trial, Not PCa related/by MaxBR111: A New ADC Therapy That Could Work Also For Prostate Cancer
/0 Comments/in Clinical Trial, Not PCa related/by MaxPioneering Korean Trial Combines Radioligand Therapy and Immunotherapy for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 2 Trial: Opaganib Plus Darolutamide for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1 Clinical Trial Recruiting: HLD-0915 a RIPTAC (Regulated Induced Proximity Targeting Chimera)
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial Will Soon Start Recruiting: ACE-232 a Promising Inhibitor of CYP11A1
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: CRB-701, A Promising Antibody-Drug Conjugate Targeting Nectin-4
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxLY4052031 and LY4101174: Other 2 Nectin-4-Targeting Therapy
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025